Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Children and Young Adults with Acute Lymphoblastic Leukemia (ALL): Real World Experience from the Center for International Blood and Marrow Transplant Research (CIBMTR) and Cellular Therapy (CT) Registry
Stephan Grupp, et al.
In the real-world, tisa-cel has similar efficacy and improved safety in pediatric ALL patients. OOS product (viability 60-80%) does not impact efficacy
